Disseminated colorectal tumor cells in organs prone to metastasis detected by new double enriched nested-PCR in comparison with recognized assays

Oncology Reports

Volumn 25, Issue 5, 2011, Pages 1421-1429

  Kraus, Magdalena C ^a   Linnemann, Ulrich ^b   Berger, Martin R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Municipal Hospital Nürnberg Nord   (Germany)

Author keywords

Colorectal carcinoma; Double enriched nested PCR; K ras codon 12 mutation; New detection method

Indexed keywords

K RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE MARROW METASTASIS; CANCER DIAGNOSIS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CODON; COLON ADENOMA; COLON CARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE ENRICHED NESTED POLYMERASE CHAIN REACTION; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RESTRICTION MAPPING; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; TUMOR CELL; WILD TYPE;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79953041554     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1203     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
4. Benson AB III, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: 3408-3419, 2004. (Pubitemid 41103700)
5. Conzelmann M, Linnemann U and Berger MR: Detection of disseminated tumour cells in the liver of colorectal cancer patients. Eur J Surg Oncol 31: 38-44, 2005. (Pubitemid 40103923)
6. Liefers GJ, Cleton-Jansen AM, Hermans J, van Krieken JH, Cornelisse CJ and Tollenaar RA: Micrometastases and survival in stage II colorectal cancer. N Engl J Med 339: 223-228, 1998. (Pubitemid 28350164)
7. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22: 1797-1806, 2004. (Pubitemid 41095169)
8. Dieterle CP, Conzelmann M, Linnemann U and Berger MR: Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients. Clin Cancer Res 10: 641-650, 2004. (Pubitemid 38174004)
9. Weitz J, Kienle P, Magener A, et al: Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow. Clin Cancer Res 5: 1830-1836, 1999.
10. Keller JW, Franklin JL, Graves-Deal R, Friedman DB, Whitwell CW and Coffey RJ: Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. J Cell Physiol 210: 740-749, 2007. (Pubitemid 46185043)
11. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
12. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
13. Conzelmann M, Linnemann U and Berger MR: Detection of disseminated tumour cells in the liver of cancer patients. Eur J Surg Oncol 31: 977-985, 2005. (Pubitemid 41671111)
14. Schimanski CC, Linnemann U and Berger MR: Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 59: 5169-5175, 1999. (Pubitemid 29503978)
15. Tortola S, Steinert R, Hantschick M, et al: Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol 19: 2837-2843, 2001. (Pubitemid 32538192)
16. Taback B, Bilchik AJ, Saha S, et al: Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer 111: 409-414, 2004. (Pubitemid 38998822)
17. Bazan V, Migliavacca M, Zanna I, et al: Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13: 1438-1446, 2002.
18. Conzelmann M, Linnemann U and Berger MR: K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients. Int J Oncol 24: 1537-1544, 2004.
19. Kraus MC, Seelig MH, Linnemann U and Berger MR: The balanced induction of K-ras codon 12 and 13 mutations in mucosa differs from their ratio in neoplastic tissues. Int J Oncol 29: 957-964, 2006.
20. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85: 692-696, 2001.
21. Lahr G: PNA clamp technique for detecting a Ki-ras2 mutation using the LightCycler instrument. Biochemica 4: 14-16, 2002.
22. Ward R, Hawkins N, O'Grady R, et al: Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-ras mutations in clinical samples. Am J Pathol 153: 373-379, 1998. (Pubitemid 28373649)
23. Calistri D, Rengucci C, Seymour I, et al: Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol 204: 484-488, 2005. (Pubitemid 40934643)
24. Finkelstein SD, Sayegh R, Christensen S and Swalsky PA: Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 71: 3827-3838, 1993.
25. Finkelstein SD, Sayegh R, Bakker A and Swalsky P: Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 128: 526-531, 1993.
26. Koch M, Kienle P, Logan E, et al: Detection of disseminated tumor cells in liver biopsies of colorectal cancer patients is not associated with a worse prognosis. Ann Surg Oncol 14: 810-817, 2007. (Pubitemid 46175331)
27. Linnemann U, Schimanski CC, Gebhardt C and Berger MR: Prognostic value of disseminated colorectal tumor cells in the liver: results of follow-up examinations. Int J Colorectal Dis 19: 380-386, 2004. (Pubitemid 38868306)
28. Andreyev HJ, Norman AR, Cunningham D, Oates JR and Clarke PA: Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 90: 675-684, 1998.
29. Toschi L and Cappuzzo F: Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 12: 211-220, 2007.
30. Uchida A, Hirano S, Kitao H, et al: Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci 98: 357-363, 2007. (Pubitemid 46195606)
31. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230-3237, 2007. (Pubitemid 47325606)
32. Lievre A, Bachet JB, Boige V, et al: KRAS mutationsas an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008. (Pubitemid 351171687)